Eltrombopag Dose Adjustment During Reactive Secondary Thrombocytosis in
patient with ITP
Abstract
Eltrombopag is relatively new drug used in Thrombocytopenia. Its dose
should be adjusted based on platelets count. It should be stopped when
platelets count reach 400,000/mm³. Here, we share our case report of
stopping Eltrombopag based on platelets increment in secondary reactive
thrombocytosis irrespective of Eltrombopag treatment.
, 
